摘要
目的探讨化疗后D-二聚体(D-D)水平在判断转移性乳腺癌疗效和预后中价值。方法检测87例转移性乳腺癌患者化疗前后血浆D-D水平,比较化疗后病情进展(PD组,n=33)和疾病缓解或稳定(非PD组,n=54)者D-D水平,并采用Cox回归评价无进展生存时间(PFS)的影响因素。结果 PD组化疗前后D-D水平均高于非PD组(P<0.01);PD组化疗后D-D升高,而非PD组降低(P<0.05)。Cox回归分析发现,化疗后D-D高水平是影响非PD患者PFS的独立危险因素;化疗后D-D高水平者中位PFS明显减少,风险比为3.396(95%CI为1.431~8.059)。结论血浆D-二聚体水平有助于预测转移性乳腺癌患者的化疗效果和预后。
Objective To investigate the clinical value of plasma D-dimer level on chemotherapeutic efficacy and prognosis in metastatic breast cancer. Methods Plasma D-dimer level in 87 female patients with metastatic breast cancer was detected before and after chemotherapy, and compared between those with progressive disease(PD group, n=33) and stable disease(non-PD group, n=58) post chemotherapy. The influence factors of progress free survival(PFS) were evaluated by Cox regression analysis. Results D-dimer level was higher in PD group than in non-PD group before and after chemotherapy(P<0.01). After chemotherapy, D-dimer level was increased in PD group but decreased in non-PD group(P<0.05). Cox regression analysis showed that post-chemotherapeutic D-dimer overexpression was the independent risk factor for PFS. The median PFS was significantly shorter in patients with post-chemotherapeutic D-dimer overexpression, with a hazard ratio of 3.396(95% CI=1.431-8.059). Conclusion Plasma D-dimer level may be useful to predict chemotherapeutic efficacy and prognosis in metastatic breast cancer.
作者
林颖欣
庞丹梅
胡倩
段海波
陈秀云
LIN Ying-xin;PANG Dan-mei;HU Qian;DUAN Hai-bo;CHEN Xiu-yun(Department of Breast Oncology,Affiliated Foshan Hospital of Sun Yat-Sen University,Foshan 528000,China)
出处
《广东医科大学学报》
2019年第6期700-703,共4页
Journal of Guangdong Medical University
